目的:探讨罗格列酮对OLETF鼠股骨病理变化及成骨细胞Bcl-xL表达的影响及机制.方法:OLETF雄性大鼠20只,定期口服葡萄糖耐量试验(OGTT)监测血糖.喂养至30周时,共有成模OLETF鼠12只,随机分为罗格列酮组和模型组(每组6只),LETO鼠8只作为对照组,各组均给药12周.处死大鼠后,测股骨灰干重比.HE染色光镜观察股骨病理变化,并运用免疫组化方法检测成骨细胞Bcl-xL蛋白表达情况.结果:与模型组相比,罗格列酮组股骨灰干重比、成骨细胞计数及Bcl-xL阳性表达强度降低(P＜0.05或P＜0.01),空骨陷窝率、破骨细胞计数升高(P＜0.01);与模型组相比,对照组股骨灰干重比、成骨细胞计数及Bcl-xL阳性表达强度升高(P＜0.05或P＜0.01),空骨陷窝率、破骨细胞计数降低(P＜0.05或P＜0.01).结论:2型糖尿病本身可影响骨组织的形成和吸收的动态平衡,使骨吸收加快而骨形成不足.罗格列酮对自发肥胖型2型糖尿病大鼠股骨有进一步的损害作用.%Objective: To investigate the effects of rosiglitazone on femur pathological change and the expression of Bcl-xL in OLETF rats. Methods: Blood glucose was determined by OGTI for 20 male OLETF rats. After 30 weeks, 12 T2DM OLETF rats were randomly divided into rosiglitazone group and model group (n=6 per group). Eight male LETO rats were used as control group. All groups were administration drugs or water via intragastrically for 12 weeks. After the rats were sacrificed, the ratio of ash weight to dry weight of femur were measured. The pathological change was observed by using optical microscope and the expression of Bcl-xL was detected with immunohistochemistry method. Results: Compared with the model group, rosiglitazone group had lower the ratio of ash weight to dry weight of femur, the amount of ostcoblast and the intensity of positive expression of B cl-xL (P＜0.05 or P＜0.0 1 ), had higher the empty osteocyte lacunae ratios and the amount of osteoclast (P＜0.01); Compared with the model group, control group had higher the ratio of ash weight to dry weight of femur, the amount of osteoblast and the intensity of positive expression of Bcl-xL (P＜0.05 or P＜0.01 ), had lower the empty osteocyte lacunae ratios and the amount of osteoclast(P＜0.05 or P＜0.01 ). Conclusion: Type 2 diabetes mellitus may interfer the balance of bone resorption and formation, leading to an increase in the bone resorption and decrease in the bone formation. Rosiglitazone has the further damage on femur in OLETF rats.
展开▼
